vTv Therapeutics (NASDAQ:VTVT) Releases Earnings Results, Misses Expectations By $0.08 EPS

vTv Therapeutics (NASDAQ:VTVT) released its quarterly earnings results on Thursday. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08), Zacks reports.

vTv Therapeutics Price Performance

Shares of VTVT stock traded up $0.76 during trading hours on Friday, reaching $35.37. The stock had a trading volume of 147,517 shares, compared to its average volume of 55,695. vTv Therapeutics has a twelve month low of $14.00 and a twelve month high of $44.00. The firm has a 50-day simple moving average of $33.36 and a 200-day simple moving average of $34.80. The firm has a market capitalization of $139.36 million, a PE ratio of -38.03 and a beta of 0.28.

Analysts Set New Price Targets

Several brokerages have issued reports on VTVT. BTIG Research upped their price objective on vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Zacks Research lowered shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. HC Wainwright dropped their target price on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a report on Thursday. Rodman & Renshaw assumed coverage on shares of vTv Therapeutics in a research report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price target on the stock. Finally, Weiss Ratings upgraded shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $55.83.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares during the period. 683 Capital Management LLC acquired a new position in shares of vTv Therapeutics during the fourth quarter worth approximately $731,000. Finally, Goldman Sachs Group Inc. bought a new position in vTv Therapeutics in the 4th quarter worth approximately $221,000. Institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.